Agreed, the author on the linked article is listed as an AI, and the article is just an AI mangling of the PR release. The PR release is directly from the group and the link ought to be changed.
The press release says they've published a paper today, but doesn't link to it or say where it was published. So if anyone has journal access and can see or share the paper let us know.
Flagged. This is a source-free article created by an "AI editor" on a fluff website. Please stop upvoting it. The drug is still in Phase I trials and has NOT released any data on the patients yet.
"Percentage of the article that is generated by AI: 63%"
I appreciate the transparency, but just raises questions for me. What parts were generated by AI? What edits were made to correct the AI? Why did they feel AI was necessary?
That is not the paper mentioned in the press release, that's a different paper on the drug published in 2018 by the same group. The current paper is here:
My reading is that they believe it works across all solid malignant tumors because malignant tumors necessarily upregulate PCNA (since it's critical to cell division). I think they are also saying that it is agnostic to the particular mutations that upregulated PCNA.
